Dr. Jogin Desai presents Eyecyte-RPE™ data at Innoxbio CGT 2025 in China, showing a 14.8-letter average gain in visual acuity and a strong safety profile.
SOPHiA GENETICS (NASDAQ: SOPH) and Complete Genomics have announced a collaboration to broaden access to precision oncology testing. The partnership will integrate the AI-powered SOPHiA DDM™ platform with Complete Genomics’ new DNBSEQ-T1+ sequencing system. This will provide a streamlined, sample-to-report workflow for the renowned MSK-IMPACT® (solid tumor) and MSK-ACCESS® (liquid biopsy) assays.
Roche announced today that its investigational oral medication, fenebrutinib, has met primary endpoints in two separate, pivotal Phase III studies for both relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). The drug significantly reduced relapse rates in RMS and slowed disability progression in PPMS, positioning it as a potential first-in-class, high-efficacy oral treatment for the two most common forms of the disease.
Merck announced promising results from its pivotal Phase 3 CORALreef HeFH trial. The study found that enlicitide, an investigational, once-daily oral PCSK9 inhibitor, significantly reduced low-density lipoprotein cholesterol (LDL-C) in adults with heterozygous familial hypercholesterolemia (HeFH). These late-breaking data were presented at the AHA Scientific Sessions 2025.
Amgen‘s cholesterol-lowering medication Repatha® (evolocumab) dramatically reduces the risk of a first major adverse cardiovascular event (MACE) in high-risk patients by 25%, according to groundbreaking [Read More…]
Gilead Sciences announced its Phase 3 ASCENT-07 trial for Trodelvy® in first-line HR+/HER2-negative metastatic breast cancer did not meet its primary endpoint of progression-free survival (PFS). However, the company reported an “early trend” favoring Trodelvy for the key secondary endpoint of overall survival (OS), and the study will continue to gather more data on this measure.
Dr. James D. Watson, the Nobel laureate who fundamentally changed biology by co-discovering the DNA double helix, has died at 97. While his 1953 breakthrough ushered in the age of modern genetics
Eli Lilly and Company announced positive Phase 2 trial results for eloralintide, its investigational once-weekly, selective amylin receptor agonist. The study met its primary endpoint, showing that adults with obesity or overweight achieved mean weight reductions of up to 20.1% over 48 weeks, compared to 0.4% with placebo. The drug also demonstrated a favorable tolerability profile, with mild-to-moderate gastrointestinal symptoms being the most common adverse events. Lilly plans to advance eloralintide to Phase 3 trials by the end of 2025.
AstraZeneca has reported strong Q3 2025 results, driven by an 11% increase in Total Revenue for the first nine months of the year. The company’s success is fueled by a 16% growth in Oncology and significant advancements in its R&D pipeline, which has seen 16 positive Phase III trials year-to-date. AstraZeneca also reiterated its full-year guidance and highlighted strategic investments, including a new $4.5 billion manufacturing facility in the US.
Amgen announced strong third-quarter 2025 financial results, with total revenues increasing 12% to $9.6 billion, driven by a 14% surge in product sales volume. While GAAP EPS rose 14% to $5.93, non-GAAP EPS saw a modest 1% increase due to a 31% jump in R&D spending to advance its late-stage pipeline, including the obesity drug MariTide.
